Article
Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.
Journal of gastroenterology - 1 Jun 2010
Nakagawa Mina, Sakamoto Naoya, Ueyama Mayumi, Mogushi Kaoru, Nagaie Satoshi, Itsui Yasuhiro, Azuma Seishin, Kakinuma Sei, Tanaka Hiroshi, Enomoto Nobuyuki, Watanabe Mamoru
Abstract excerpt
BACKGROUND: Pegylated-interferon-alpha 2b (PEG-IFN) plus ribavirin (RBV) therapy is currently the de-facto standard treatment for hepatitis C virus (HCV) infection. The aims of this study were to analyze the clinical and virological factors associated with a higher rate of response in patients with HCV genotype 1b infection treated with combination therapy. METHODS: We analyzed, retrospectively, 239 patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.